drugset / Trial / NCT02690844

Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome

NCT02690844

Phase 4 Withdrawn University of Alberta
RandomizedParallel-groupSingle-blindTreatment

Summary

What affect does the use of a mucoadhesive drug delivery system (Mucolox®) compounded with clonazepam have in the treatment of burning mouth syndrome? There are no clinical trials reported in the literature that evaluate the use of a mucoadhesive vehicle to deliver clonazepam into the oral cavity and treat burning mouth syndrome. The use of a mucoadhesive may help to increase surface contact and elicit a greater reduction in symptoms.

Timeline

Start
2016-04
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonazepam Small molecule 1 mg Other